Abstract

Assisted reproductive technology (ART) treatment accounted for 6% of total births in 2017 and is increasing which places Japan among the top worldwide in number of treatments performed. Although ART treatment patients often experience heavy physical and psychological burden, few epidemiologic studies have been conducted in Japan. We examined mental health and health-related quality of life (QOL) among women at early stages of treatment. We recruited 513 women who have initiated ART treatment, either in-vitro fertilization or intracytoplasmic sperm injection, from four medical facilities in the Tokyo area and through web-based approaches. At baseline, we collected socio-demographic information and assessed depressive symptoms, anxiety, and QOL. Descriptive analyses were performed overall and stratified by factors such as age. Mild depressive symptoms or worse, assessed with Quick Inventory of Depressive Symptoms, were observed among 54% of participants. Mean score for State-Trait Anxiety Inventory was 52 with a standard deviation of 11 for the state, and 39% were categorized as high anxiety. QOL results, assessed with SF-12, showed the same negative tendency for social functioning and role (emotional), while general health and physical functioning were consistent with the national average. Young participants appeared to suffer mentally more than older participants (p < 0.01 for depressive symptoms). Our findings suggest that patients may be at high risk of depressive symptoms, high anxiety, and low QOL even from the early stages of ART treatment.

Highlights

  • Assisted reproductive technology (ART) treatment accounted for 6% of total births in 2017 and is increasing which places Japan among the top worldwide in number of treatments performed

  • ART treatments; in this report, we introduce the design and methodological features of this ongoing study, and describe the depressive symptoms, anxiety, and quality of life (QOL), as well as socio-demographic characteristics of women who are in early stages of ART treatment

  • We provided a first report focused on depressive symptoms, anxiety, and QOL as well as socio-demographic profiles of women who were starting or had just started ART treatments

Read more

Summary

Introduction

Assisted reproductive technology (ART) treatment accounted for 6% of total births in 2017 and is increasing which places Japan among the top worldwide in number of treatments performed. Our findings suggest that patients may be at high risk of depressive symptoms, high anxiety, and low QOL even from the early stages of ART treatment. The number of births by assisted reproductive technology (ART), such as in-vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), have increased steadily during the past 20 years from 12,274 in 2000 to 56,617 in 2017, currently accounting for about. ­ igh[3,4], in which treatment over one cycle costs between 300,000 and 500,000 Yen (approximately 3000–5000 US dollars) or more in Japan according to a 2018 s­ urvey[5] This is an out of pocket expense because medical insurance is not applicable to ART in Japan. Despite the high cost of ART treatment, the reality is that having a child still may not be the outcome: 16% (3555 births/21,939 embryo transfers) success with conventional IVF and 24% (46,396 births/194,415 embryo transfers) success with frozen embryo transfer according to 2017 national d

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call